Cephalon appoints new CEO

FRAZER, Pa. — Cephalon on Thursday appointed Kevin Buchi as CEO and a member of the company's board.

The board will address the role of company chairman in the future, Cephalon stated in a press release. William Egan will continue to serve as Cephalon's independent presiding director.

"Kevin is an experienced pharmaceutical executive who has been involved in every aspect of running our business," Egan stated. "Over the course of many years, Kevin worked closely with Frank Baldino Jr. to create the company that we know today, and he has the passion, leadership skills, organizational abilities and unwavering commitment to patients that are critical to ensuring Cephalon's continued growth and success." 

Buchi, who has been with Cephalon for almost 20 years, had assumed day-to-day chief executive responsibilities for the company in August 2010. He previously served as a member of the Cephalon executive management team in the roles of COO and CFO. Additionally, for the last seven years, he has led the business development function with responsibility for mergers, acquisitions and in-licensing of products.

"Cephalon is an extraordinary company with one of the most robust pipelines in the industry focused on patients suffering from rare disorders and diseases for which there are no cures,” Buchi said. “We have expanded our global footprint dramatically in the last few years. I am confident that our diverse product portfolio, rich pipeline and global presence position us well for long-term growth and success."